knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 17:04:25 - browse：15945

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA proposes changes to key medical devices approval pathway

WSS

Will the IRA bring competition to the biologics market?

Generate Biomedicines machine learning biotech raises $273M

Telehealth for opioid use disorder is lifesaving

Biotech lab space demand falls sharply

Senators: Long

Readout LOUD podcast: possible new ALS drug, artificial wombs

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

What does generative AI mean for health care? We asked experts

FDA panel endorses Alnylam’s heart drug — after picking it apart

Medicare proposal to cover medical devices draws a mixed reaction

WATCH: Why do bright lights make us see spots?

Bright Health sells Medicare Advantage business to Molina

Microbiome research is starting to find links to chronic diseases

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Medical leaders decry Supreme Court decision on affirmative action

Will the IRA bring competition to the biologics market?

hotspot

CommonSpirit Health keeps growing, even as it loses money

How AI helped researchers track recovery from depression

Will the IRA bring competition to the biologics market?

Acelyrin, a rare IPO success, stumbles in its first big test

Popular nasal decongestant doesn't actually relieve congestion

Generate Biomedicines machine learning biotech raises $273M

hotspot

Wikipedia

explore

hotspot